NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be ...
ATLANTA -- Are neurostimulators implanted within the brain a better approach in epilepsy than less-invasive vagus nerve stimulation (VNS)? That depends, a researcher said. Real-world data from two ...
-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, affecting a significant proportion of patients who develop drug-resistant epilepsy. Surgical interventions, particularly ...
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy, affecting a significant proportion of patients who develop drug-resistant epilepsy. Surgical interventions, particularly ...
NeuroPace (NASDAQ:NPCE) reported fourth-quarter and full-year 2025 results that management said reflected sustained momentum in its core RNS business, improving margins, and continued progress toward ...
DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results